"AS-19 (drug)"

Covid-19 drugs and vaccines: big money and winning alliances Prescrire IN ENGLISH - Spotlight ''Covid-19 drugs and vaccines: big money and winning alliances'', 1 June 2021 {1}##LOC[OK]## {1} ##LOC[OK]## ##LOC[Cancel]## {1}##LOC[OK]####LOC[Cancel]## Register online| Log in| My Prescrire Issue contents * Current issue * Last 12 issues * All issues Topics * Annual Prescrire Awards * Subscribers: register online * Prescrire's other products * Free Special Edition * Sign up to receive the newsletter english.prescrire.org > Spotlight > 100 most recent > Covid-19 drugs and vaccines: big money and winning alliances SpotlightEvery month, the subjects in Prescrire’s Spotlight. 100 most recent: 1|10|20|30|40|50|60|70|80|90Spotlight * 100 most recent * ArchivesCovid-19 drugs and vaccines

Covid-19 drug vignettes: Azithromycin Drug vignettes: Azithromycin - The Centre for Evidence-Based Medicine The Centre for Evidence-Based MedicineEvidence Service to support the COVID-19 responseNavigate this website * Home * COVID-19 Evidence * Open Evidence Reviews * Blog * Home * COVID-19 Evidence * Open Evidence Reviews * BlogDrug vignettes: AzithromycinMay 13, 2020Robin E Ferner*, Jeffrey K

Covid-19: Drug vignettes: Interferons Drug vignettes: Interferons - The Centre for Evidence-Based Medicine The Centre for Evidence-Based MedicineEvidence Service to support the COVID-19 responseNavigate this website * Home * COVID-19 Evidence * Open Evidence Reviews * Blog * Home * COVID-19 Evidence * Open Evidence Reviews * BlogDrug vignettes: InterferonsAugust 6, 2020Jeffrey K Aronson

Covid-19: Drug vignettes: Remdesivir Drug vignettes: Remdesivir - The Centre for Evidence-Based Medicine The Centre for Evidence-Based MedicineEvidence Service to support the COVID-19 responseNavigate this website * Home * COVID-19 Evidence * Open Evidence Reviews * Blog * Home * COVID-19 Evidence * Open Evidence Reviews * BlogDrug vignettes: RemdesivirAugust 10, 2020Updated 23 September 2020

Covid-19: Drug vignettes: Tocilizumab Drug vignettes: Tocilizumab - The Centre for Evidence-Based Medicine The Centre for Evidence-Based MedicineEvidence Service to support the COVID-19 responseNavigate this website * Home * COVID-19 Evidence * Open Evidence Reviews * Blog * Home * COVID-19 Evidence * Open Evidence Reviews * BlogDrug vignettes: TocilizumabMay 1, 2020Robin E Ferner*, Jeffrey K

Real-world prescription of anti-COVID-19 drugs in hospitalized patients with COVID-19 in Japan. Prescription trends and patterns of anti-COVID-19 drugs in hospitalized patients were examined based on real world data to understand the use of anti-COVID-19 drugs in clinical practice in Japan. The longitudinal and cross-sectional study was conducted utilizing data from January 1, 2019 to December 31, 2021 of the MID-NET® medical information database, which stored the electronic medical records, administrative claim data, and diagnosis procedure combination data of patients in Japan. Hospitalized patients with a COVID-19-related diagnosis who received at least one anti-COVID-19 drug between April 1, 2020 and December 31, 2021. The following 14 drugs were included in this study: remdesivir

Concerted and multidisciplinary management of COVID-19 drug therapies during the first two epidemic waves in a tertiary hospital in Marseille, France: Results of the PHARMA-COVID study. To evaluate the impact of local therapeutic recommendation updates made by the COVID multidisciplinary consultation meeting (RCP) at the Hôpital Européen Marseille (HEM) through the description of the drug into clinical trials. The effective dissemination of evidence-based and concerted recommendations seems to have allowed an optimized management of COVID-19 drug therapies in the context of this emerging infection with rapidly evolving therapeutic questions.

Toxicity Evaluation and Effect-Based Identification of Chlorine Disinfection Products of the Anti-COVID-19 Drug Chloroquine Phosphate. Antiviral transformation products (TPs) generated during wastewater treatment are an environmental concern, as their discharge, in considerable amounts, into natural waters during a pandemic can pose possible risks to the aquatic environment. Identification

COVID-19 drug research and the cohort multiple randomised controlled trial design. https://bit.ly/3xtBX3m

Reply: COVID-19 drug research and the cohort multiple randomised controlled trial design. https://bit.ly/39Obd4N

Anti-inflammatory effect of Kaba Sura Kudineer (AYUSH approved COVID-19 drug)-A Siddha poly-herbal formulation against lipopolysaccharide induced inflammatory response in RAW-264.7 macrophages cells. Medicinal importance and potential activity of Siddha herbal formulations have proved over several centuries against a wide range of causative agents as Influenza, Dengue, Chikungunya

Outpatient prescription patterns of COVID-19 drugs in the metropolitan area of Mexico City. We aimed to describe the use of drugs with apparent efficacy in ambulatory patients with confirmed COVID-19 and the relationship of Google Trends searches with prescriptions and the total number of COVID-19 cases in Mexico City. Between March 2020 and February 2021, we surveyed 350 patients confirmed

The Anti-COVID-19 Drug Remdesivir Promotes Oncogenic Herpesvirus Reactivation through Regulation of Intracellular Signaling Pathways. Recently, remdesivir and molnupiravir were approved for treating COVID-19 caused by SARS-CoV-2 infection. However, little is known about the impact of these drugs on other viruses preexisted in COVID-19 patients. Here we report that remdesivir but not molnupiravir

Artificial intelligence in COVID-19 drug repurposing. Drug repurposing or repositioning is a technique whereby existing drugs are used to treat emerging and challenging diseases, including COVID-19. Drug repurposing has become a promising approach because of the opportunity for reduced development timelines and overall costs. In the big data era, artificial intelligence (AI) and network medicine AI models can accelerate COVID-19 drug repurposing. Rapidly developing, powerful, and innovative AI and network medicine technologies can expedite therapeutic development. This Review provides a strong rationale for using AI-based assistive tools for drug repurposing medications for human disease, including during the COVID-19 pandemic.

CYP3A4/UGT substrates by inducers (e.g., anti Covid-19 drugs, antiseizure medications) based on sensitive CYP3A4 substrate and UGT substrate data: systematic review and correlation analyses PROSPEROInternational prospective register of systematic reviews Print | PDFCYP3A4/UGT substrates by inducers (e.g., anti Covid-19 drugs, antiseizure medications) based on sensitive CYP3A4 substrate and UGT substrate data: systematic review and correlation analysesSara Eyal, Hagar Cohen, Amnah Mhagne, Ilan MatokCitationSara Eyal, Hagar Cohen, Amnah Mhagne, Ilan Matok. CYP3A4/UGT substrates by inducers (e.g., anti Covid-19 drugs, antiseizure medications) based on sensitive CYP3A4 substrate and UGT substrate data: systematic review and correlation analyses. PROSPERO 2024 CRD42024513792 Available from: https

A living guidance for COVID-19 drug treatment based on an umbrella review A living guidance for COVID-19 drug treatment based on an umbrella review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied

Effectiveness and safety of baricitinib as a covid-19 drug candidate: a systematic review Effectiveness and safety of baricitinib as a covid-19 drug candidate: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms

/substance-use/controlled-illegal-drugs/methamphetamine.html Accessed October 30, 2023.Hoj SB, Minoyan N, Zang G, Larney S, Bruneau J. Gender, sexual orientation identity, and initiation of amphetamine injecting among people who inject drugs: Examination of an expanding drug era in Montreal, Canada, 2011–19. Drug & Alcohol Dependence. 2023;251:110956.Bach P, Hayashi K, Milloy MJ, Nosova E, Kerr T, Wood E

of patients with COVID-19. https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/ (Accessed March 21, 2022). Google Scholar8. Ontario COVID-19 Drugs and Biologics Clinical Practice Guidelines Working Group. Therapeutic management of adult patients with COVID-19. https://covid19-sciencetable.ca/wp-content/uploads/2022/01/Clinical-Practice-Guidelines_Update_20220118.pdf -safety-and-availability/fda-updates-sotrovimab-emergency-use-authorization (Accessed April 20, 2022). Google Scholar22. Ontario COVID-19 Drugs and Biologics Clinical Practice Guidelines Working Group. Clinical practice guideline summary: Recommended drugs and biologics in adult patients with COVID-19. Ontario COVID-19 Science Advisory Table. Version 11. https://covid19-sciencetable.ca/sciencebrief